Boosting its Phase I Clinical Trial Service Capability
HANGZHOU, China, Dec. 1 /PRNewswire-Asia/ -- Tigermed Consulting Co., Ltd, a leading Contract Research Organization (CRO) in China, announced that it has established a subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd, with Central South University (CSU). The establishment of Tigermed Xiangya marks Tigermed's participation in the construction of a nationwide first-rate Phase I Clinical Laboratory, and further substantiates Tigermed's service ability in drug pre-clinical studies and pharmaceutical analysis. This new cooperation allows Tigermed to provide more extensive and comprehensive outsourcing clinical services for Multinational Pharmaceutical Corporations and Local Research Institutions in the research and development of innovative drugs.
Tigermed, staffed with a team of 100 plus professionals, is dedicated to providing such all-round services as Phase I-IV clinical trials, data management & statistical analysis and regulatory affairs, and Tigermed has accumulated outstanding experience in the clinical trials of innovative drugs. In July 2008, financed by Qiming Ventures, an internationally renowned venture capital organization, Tigermed entered into a period of rapid expansion.
Xiangya Medical College, predecessor of Xiangya Medical School of CSU, was founded in 1914 as one of the early western medicine colleges and universities in China, and enjoyed a high reputation as "South Xiangya, North Union", widely recognizing that Xiangya Medical College in the south and Peking Union Medical College in the north of China are the most two famous medical institutions. Currently, Xiangya Medical School of CSU has three affiliated tertiary hospitals, 8 clinical colleges and 24 stable teaching bases. Phase I Clinical Laboratory of the Drug Clinical Trial Agency in the third Xiangya Hospital of CSU is one of the first groups of Laboratories passing preliminary examination.
Tigermed Xiangya has three Evaluation Centers: the Drug Clinical Evaluation Center (DCEC), Pharmaceutical Analysis Center (PAC) and Drug Pre- clinical Evaluation Center (DPEC). DCEC mainly cooperates with the third Xiangya Hospital of CSU to conduct Phase I clinical trials for new drugs, and Pharmacokinetics (PK) and Bioequiavailability (BE) studies in other stages of clinical trials. PAC is chiefly responsible for the studies related to pharmaceutical analysis. DPEC is principally in charge of PK screening of compound candidates; PK studies, Pharmacodynamics (PD) studies, quality specification studies, and manufacturing process studies during pre-clinical studies.
Professor Cheng Zeneng, Deputy Dean of the School of Pharmacy of CSU, Director of Drug Metabolism and Pharmacokinetics Research Institute, Deputy Director of Phase I Clinical Laboratory of the Drug Clinical Trial Agency in the third Xiangya Hospital of CSU, expressed, "CSU and its affiliated hospitals are equipped with high technologies and abundant resources, in complementary, Tigermed has sufficient funds and rich management expertise, so we are quite confident of building up Tigermed Xiangya as a leading Drug Clinical Evaluation Center in China."
"To set up Tigermed Xiangya is a significant move for us to complete our clinical service chain and this union of two titans will tremendously boost Tigermed's serviceability in Phase I clinical trials," comments Ms Cao Xiaochun, Vice President of Tigermed, "We are looking forward to the great future of Tigermed Xiangya, and it will be the first trial and a unique pioneering effort in China's CRO industry".
For more information, please contact:
Zeng Haiyan
Tel: +86-571-8998-6792
Email: pr@tigermed.net
SOURCE Tigermed Consulting Co., Ltd
International News / Press Release source: PR Newswire
Copyright PR Newswire. All Rights Reserved.